# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ZAPP: 40% | Zapp Electric Vehicles shares are trading higher after the company announced that it entered into a new standby equ...
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Ke...
Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to ...
Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...